

FOI 4082

Cancer Treatment in Secondary Care

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available? 1st Feb 2026 – 30th April 2026

Name of medicine	Number patients treated
1.1 Avelumab (Bavencio)	0
1.2 Atezolizumab (Tecentriq)	8
1.3 Pembrolizumab (Keytruda)	37
1.4 Nivolumab (Opdivo)	1
1.5 Durvalumab (Imfinzi)	2
1.6 Erdafitinib (Balversa)	0
1.7 Enfortumab vedotin (Padcev)	3
1.8 Cisplatin	0
1.9 Carboplatin	30
1.10 Gemcitabine	1

Q2. How many patients were treated with avelumab (Bavencio) for the following types of cancer in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available? 1st Feb 2026 – 30th April 2026

Name of monotherapy or combination	Number patients treated
Merkel Cell Carcinoma (ICD-10 codes = C4A* and/or morphology code = 8247/3)	0
Urothelial Carcinoma (ICD-10 codes = C65*, C66*, C67* and/or morphology code = 8120*, 8130*, 8131/3, 8122/3, 8031/3)	0
Renal Cell Carcinoma (C64*)	0
Other types of tumour	0

Q3. How many patients with Renal Cell Carcinoma (RCC) were treated with the following medicines, in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available? 1st Feb 2026 – 30th April 2026

Name of monotherapy or combination	Number patients treated
3.1 Avelumab + Axitinib	0

Q4. How many patients with Urothelial Carcinoma (UC) were treated with the following medicines, in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available? 1st Feb 2026 – 30th April 2026

Name of monotherapy or combination	Number patients treated
4.1 Avelumab Monotherapy Maintenance	0
4.2 Atezolizumab	0
4.3 Pembrolizumab Monotherapy	0
4.4 Pembrolizumab + Enfortumab vedotin	3
4.5 Nivolumab Monotherapy	0
4.6 Nivolumab + Cisplatin + Gemcitabine	0
4.7 Durvalumab Monotherapy Maintenance	0
4.8 Durvalumab + Gemcitabine + Cisplatin	0
4.9 Carboplatin+ Gemcitabine	0
4.10 Paclitaxel Monotherapy	0
4.11 Carboplatin + Paclitaxel	0
4.12 Cisplatin + Gemcitabine	0

Q5. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available? 1st Feb 2026 – 30th April 2026

Name of medicine	Number patients treated
5.1 Aflibercept – (Zaltrap only)	0
5.2 Bevacizumab	22
5.3 Cetuximab	15
5.4 Encorafenib	4
5.5 Fruquintinib	2
5.6 Nivolumab	1
5.7 Panitumumab	1
5.8 Pembrolizumab	37
5.9 Regorafenib	0
5.10 Trifluridine + Tipiracil (Lonsurf)	30

Q6. How many patients were treated for Colorectal Cancer (ICD-10 codes C18*, C19*, C20*, D010, D011, D012) with the following medicines in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available? 1st Feb 2026 – 30th April 2026

Name of medicine	Number patients with CRC treated
6.1 Bevacizumab	22
6.2 Cetuximab	15
6.3 Encorafenib	4
6.4 Nivolumab	1
6.5 Pembrolizumab	7
6.6 Regorafenib	0
6.7 Trifluridine + Tipiracil (Lonsurf)	30

Q7. How many patients were treated for Colorectal Cancer (ICD-10 codes C18*, C19*, C20*, D010, D011, D012) with the following combinations or chemotherapy and other agents in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available? 1st Feb 2026 – 30th April 2026

Name of chemotherapy combination	Number patients with CRC treated
7.1 Bevacizumab + Trifluridine + Tipiracil	19
7.2 Bevacizumab + FOLFOX	2
7.3 Bevacizumab + FOLFIRI	0
7.4 Cetuximab + FOLFIRI	11
7.5 Cetuximab + FOLFOX	0
7.6 Cetuximab + FOLFIRINOX / FOLFOXIRI	0
7.7 Cetuximab Monotherapy	0
7.8 Panitumumab + FOLFIRI	0
7.9 Panitumumab + FOLFOX	1
7.10 Panitumumab + FOLFIRINOX / FOLFOXIRI	0
7.11 Capecitabine + Oxaliplatin (XELOX)	7
7.12 Capecitabine + Irinotecan (XELIRI)	6